# China NMPA Drug Inspection - Kunming Jingtian Pharmaceutical Co., Ltd. - Epimedium

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/kunming-jingtian-pharmaceutical-co-ltd/78285a9d-5c5f-4068-9eb2-b17bbb5f3094/
Source feed: China

> China NMPA drug inspection for Kunming Jingtian Pharmaceutical Co., Ltd. published December 29, 2020. Drug: Epimedium. The Guizhou Provincial Drug Administration published its fourth Drug Quality Announcement of 2020 on December 29, 2020, 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Guizhou Provincial Drug Administration Drug Quality Bulletin (Drug Sampling Inspection Information Announcement) (Issue 4, 2020) (Total Issue 42)
- Company Name: Kunming Jingtian Pharmaceutical Co., Ltd.
- Publication Date: 2020-12-29
- Drug Name: Epimedium
- Inspection Finding: The non-compliance item is: total ash content.
- Action Taken: Drug regulatory authorities at all levels shall, in accordance with relevant laws and regulations, investigate and prosecute drugs that fail to meet the standards in random inspections within their jurisdictions, strengthen supervision of relevant entities, urge them to correct illegal activities, and enhance risk prevention and control.
- Summary: The Guizhou Provincial Drug Administration published its fourth Drug Quality Announcement of 2020 on December 29, 2020, detailing the results of provincial drug sampling inspections. Conducted under the framework of the Drug Administration Law of the People's Republic of China and the Administrative Measures for Drug Quality Sampling Inspection, the oversight initiative identified four batches of non-compliant traditional Chinese medicine products from three specific manufacturers. Bozhou Zhongqiang Traditional Chinese Medicine Pieces Co., Ltd. was cited for Gentian Root that failed moisture standards. Kunming Jingtian Pharmaceutical Co., Ltd. had two products cited: Drynaria, which failed property and identification tests, and Epimedium, which exceeded limits for total ash content. Finally, Jiangxi Heshuo Pharmaceutical Co., Ltd. produced salt-processed Psoralea that failed content determination requirements. All identified violations were measured against the standards set in the 2015 edition of the Chinese Pharmacopoeia. In response to these findings, the Guizhou Provincial Drug Administration has mandated that local regulatory departments initiate legal investigations and prosecutions against the responsible parties. The involved companies are required to implement immediate corrective actions, rectify illegal activities, and strengthen their internal risk prevention and control mechanisms to ensure the future safety and quality of public medications.

Company: https://www.globalkeysolutions.net/companies/kunming-jingtian-pharmaceutical-co-ltd/e21da34c-2a29-4bbf-9bb9-05e621ed0b33/